Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy
Journal for ImmunoTherapy of Cancer · 2024-10 · 12 (10) · e009934
DOI: 10.1136/jitc-2024-009934 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 31.10.2024. Verfasst von Yan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Killer Cells, Natural, Neoplasms, NK Cell Lectin-Like Receptor Subfamily C, Immunotherapy. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shenzhen Medical Research Fund, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immune checkpoint blockade, which enhances the reactivity of T cells to eliminate cancer cells, has emerged as a potent strategy in cancer therapy. Besides T cells, natural killer (NK) cells also play an indispensable role in tumor surveillance and destruction. NK Group 2 family of receptor A (NKG2A), an emerging co-inhibitory immune checkpoint expressed on both NK cells and T cells, mediates inhibitory signal via interaction with its ligand human leukocyte antigen-E (HLA-E), thereby attenuating the effector and cytotoxic functions of NK cells and T cells. Developing antibodies to block NKG2A, holds promise in restoring the antitumor cytotoxicity of NK cells and T cells. In this review, we delve into the expression and functional significance of NKG2A and HLA-E, elucidating how the NKG2A-HLA-E axis contributes to tumor immune escape via signal transduction mechanisms. Furthermore, we provide an overview of clinical trials investigating NKG2A blockade, either as monotherapy or in combination with other therapeutic antibodies, highlighting the responses of the immune system and the clinical benefits for patients. We pay special attention to additional immune co-signaling molecules that serve as potential targets on both NK cells and T cells, aiming to evoke more robust immune responses against cancer. This review offers an in-depth exploration of the NKG2A-HLA-E pathway as a pivotal checkpoint in the anti-tumor responses, paving the way for new immunotherapeutic strategies to improve cancer patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.
- Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.
- Department of Dermatology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.
- Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.
- Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, Netherlands.
- Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China estelly88@gmail.com zhougy9@mail.sysu.edu.cn.
ORCID-Profile: Wanhua Feng, Guoying Zhou
Förderung
- Shenzhen Medical Research Fund
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Li, Y., Li, Z., Tang, Y., Zhuang, X., Feng, W., Boor, P. P. C., Buschow, S., Sprengers, D., & Zhou, G. (2024). Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 12(10), e009934. https://doi.org/10.1136/jitc-2024-009934
Vancouver
Li Y, Li Z, Tang Y, Zhuang X, Feng W, Boor PPC, et al. Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 2024;12(10):e009934. doi:10.1136/jitc-2024-009934
BibTeX
@article{Li2024,
author = {Li, Yan and Li, Zhu and Tang, Yisen and Zhuang, Xiaomei and Feng, Wanhua and Boor, Patrick P C and Buschow, Sonja and Sprengers, Dave and Zhou, Guoying},
title = {Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {10},
pages = {e009934},
doi = {10.1136/jitc-2024-009934}
}
EUVIMED